Clinical Trial Detail

NCT ID NCT03003962
Title Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Carboplatin + Pemetrexed Disodium

Cisplatin + Pemetrexed Disodium

Carboplatin + Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST